C M Rubino

Summary

Affiliation: Ordway Research Institute
Country: USA

Publications

  1. pmc Population pharmacokinetic model for gatifloxacin in pediatric patients
    Christopher M Rubino
    Cognigen Corporation, Buffalo, NY, USA
    Antimicrob Agents Chemother 51:1246-52. 2007
  2. ncbi request reprint Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206, USA
    Diagn Microbiol Infect Dis 59:67-74. 2007
  3. ncbi request reprint Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206 1072, USA
    Paediatr Drugs 9:361-9. 2007
  4. ncbi request reprint Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults
    C M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, 43 British American Boulevard, Latham, NY 12110, USA
    Pulm Pharmacol Ther 22:279-85. 2009
  5. pmc Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Inc, Albany, New York, USA
    Antimicrob Agents Chemother 53:4422-8. 2009
  6. pmc Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections
    S M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, 43 British American Blvd, Latham, NY 12110, USA
    Antimicrob Agents Chemother 54:1207-12. 2010
  7. ncbi request reprint Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206 1072, USA
    Diagn Microbiol Infect Dis 62:99-101. 2008
  8. ncbi request reprint Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Clin Infect Dis 44:79-86. 2007
  9. pmc Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, 150 New Scotland Avenue, Albany, NY 12208, USA
    Antimicrob Agents Chemother 51:4085-9. 2007
  10. ncbi request reprint Population Pharmacokinetic Analyses for BC-3781 Using Phase 2 Data from Patients with Acute Bacterial Skin and Skin Structure Infections
    C M Rubino
    Institute for Clinical Pharmacodynamics Inc, Latham, New York, USA
    Antimicrob Agents Chemother 59:282-8. 2015

Detail Information

Publications13

  1. pmc Population pharmacokinetic model for gatifloxacin in pediatric patients
    Christopher M Rubino
    Cognigen Corporation, Buffalo, NY, USA
    Antimicrob Agents Chemother 51:1246-52. 2007
    ..The success of this strategy provides a model for future pediatric drug development programs...
  2. ncbi request reprint Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206, USA
    Diagn Microbiol Infect Dis 59:67-74. 2007
    ..In conclusion, population pharmacokinetic/pharmacodynamic methods allowed estimation of drug exposure using one sample per patient...
  3. ncbi request reprint Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206 1072, USA
    Paediatr Drugs 9:361-9. 2007
    ..Application of these PK-PD principles allows rational dosage regimen selection, both for serious infections in critically ill children and for non-life-threatening community-acquired infections...
  4. ncbi request reprint Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults
    C M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, 43 British American Boulevard, Latham, NY 12110, USA
    Pulm Pharmacol Ther 22:279-85. 2009
    ..Administration of pirfenidone with food has a modest effect on overall exposure but results in lower peak concentrations, which may improve tolerability...
  5. pmc Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Inc, Albany, New York, USA
    Antimicrob Agents Chemother 53:4422-8. 2009
    ..These results suggest that dose modification may be warranted in patients weighing >110 kg. However, the mild nature of the observed relationships for Vc suggest that dosing adjustments are not necessary for elderly patients...
  6. pmc Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections
    S M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, 43 British American Blvd, Latham, NY 12110, USA
    Antimicrob Agents Chemother 54:1207-12. 2010
    ..594. These findings demonstrated the impact of individual and multiple factors on clinical response in the context of drug exposure...
  7. ncbi request reprint Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206 1072, USA
    Diagn Microbiol Infect Dis 62:99-101. 2008
    ..Such data may be useful to establish prior expectations for the no-treatment effect when conducting noninferiority clinical trials...
  8. ncbi request reprint Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Clin Infect Dis 44:79-86. 2007
    ..Over the past 15 years, considerable PK-PD data have been derived from infected patients for many classes of antimicrobial agents. These data provide the opportunity to confirm knowledge gained from animal PK-PD infection models...
  9. pmc Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, 150 New Scotland Avenue, Albany, NY 12208, USA
    Antimicrob Agents Chemother 51:4085-9. 2007
    ..15 (0.561 and 5.23), respectively. Simulation results predict that tissue penetration varies considerably and likely explain unexpected clinical outcomes for those patients infected with strains at margins of the MIC distribution...
  10. ncbi request reprint Population Pharmacokinetic Analyses for BC-3781 Using Phase 2 Data from Patients with Acute Bacterial Skin and Skin Structure Infections
    C M Rubino
    Institute for Clinical Pharmacodynamics Inc, Latham, New York, USA
    Antimicrob Agents Chemother 59:282-8. 2015
    ..This population PK model will be useful for subsequent PK-pharmacodynamic analyses and simulations conducted to support phase 3 dose selection. (This study has been registered at ClinicalTrials.gov under registration no. NCT01119105.). ..
  11. pmc Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model
    Stanley C Gill
    Department of Pharmacology, Replidyne, Inc, Louisville, Colorado, USA
    Antimicrob Agents Chemother 54:1678-83. 2010
    ..6, 13.4, and 16.4%, respectively, and E(max) was 89.3%. Overall, faropenem demonstrated a high level of activity against B. anthracis in the murine postexposure prophylaxis inhalation model...
  12. ncbi request reprint Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, New York, USA
    Clin Infect Dis 50:1568-74. 2010
    ....
  13. pmc Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 47:292-6. 2003
    ..pneumoniae and that gatifloxacin has an overall 14.3% higher probability of achieving clinically important PK-PD target ratios than levofloxacin...